Genmab A/S Sees Unusually Large Options Volume (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the target of some unusual options trading activity on Tuesday. Stock investors bought 4,639 call options on the company. This represents an increase of 332% compared to the average volume of 1,074 call options.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently made changes to their positions in the business. CIBC Private Wealth Group LLC lifted its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the period. Osaic Holdings Inc. raised its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares in the last quarter. V Square Quantitative Management LLC bought a new position in Genmab A/S in the 1st quarter worth $34,000. NewEdge Advisors LLC lifted its position in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. lifted its position in shares of Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Up 1.7%

Shares of Genmab A/S stock traded up $0.43 during trading on Tuesday, reaching $26.04. 499,780 shares of the stock were exchanged, compared to its average volume of 1,790,847. Genmab A/S has a 1 year low of $20.23 and a 1 year high of $35.43. The firm has a market cap of $16.23 billion, a price-to-earnings ratio of 19.71, a price-to-earnings-growth ratio of 1.50 and a beta of 0.85. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The stock’s fifty day moving average is $26.44 and its 200 day moving average is $28.95.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Truist Financial began coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price objective for the company. Guggenheim decreased their target price on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, February 23rd. Wolfe Research started coverage on shares of Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price target for the company. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Finally, Wells Fargo & Company began coverage on Genmab A/S in a research note on Monday, March 2nd. They set an “overweight” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.93.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.